NCT03074513 2026-03-11Atezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsM.D. Anderson Cancer CenterPhase 2 Active not recruiting133 enrolled
NCT03228667 2026-01-14QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsImmunityBio, Inc.Phase 2 Active not recruiting40 enrolled
NCT04157985 2025-12-11Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid TumorsUniversity of PittsburghPhase 3 Completed161 enrolled
NCT03901573 2025-10-22High-Risk Skin Cancers With Atezolizumab Plus NT-I7NeoImmuneTechPhase 1/2 Terminated31 enrolled 12 charts
NCT03841110 2023-05-01FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsFate TherapeuticsPhase 1 Completed37 enrolled
NCT05429866 2023-03-08Immunological Variables Associated to ICI Toxicity in Cancer PatientsJules Bordet InstitutePhase 2 Unknown441 enrolled
NCT03544723 2020-06-09Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.MultiVir, Inc.Phase 2 Unknown40 enrolled